A phase 1/2a open-label study to evaluate OPM-101 (ODS-101) in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Apr 2025 New trial record
24 Mar 2025 According to Oncodesign Precision Medicine media release, company announced the submission to Swiss authorities of the study protocol for its Phase 1b/2a clinical trial.Submission of the application for authorization of the clinical study to the Swiss regulatory authorities (Swissmedic) and to the Ethics Committees of the centers involved in phase 1b of the study, was completed on March 24, 2025.
24 Mar 2025 According to Oncodesign Precision Medicine media release, company announced the submission to Swiss authorities of the study protocol for its Phase 1b/2a clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com